Pulmonary Cell News Volume 11.36 | Sep 15 2022

    By
    Danielle Corrigan
    -
    0
    22








    2022-09-15 | PULCN 11.36


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 11.36 – 15 September, 2022
    TOP STORY

    P130cas-FAK Interaction Is Essential for YAP-Mediated Radioresistance of Non-Small Cell Lung Cancer

    The authors found that P130cas promoted proliferation, altered the cell cycle profile, and enhanced tumor growth using cell lines and xenograft mouse models.
    [Cell Death & Disease]

    Full Article

    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    PUBLICATIONSRanked by the impact factor of the journal

    Multi-Apical Polarity of Alveolar Stem Cells and Their Dynamics during Lung Development and Regeneration

    Scientists proposed that the multi-apical domains of alveolar type-2 epithelial cells enabled them to be poised to support the regeneration of a large array of alveolar sacs.
    [iScience]

    AbstractFull ArticleGraphical Abstract

    IL-37 Protects against Airway Remodeling by Reversing Bronchial Epithelial–Mesenchymal Transition via IL-24 Signaling Pathway in Chronic Asthma

    BEAS-2B cells were exposed to IL-24, and cell migration was assessed by wound healing and Transwell assays. The expression of epithelial-mesenchymal transition-related biomarkers was evaluated after the cells were stimulated with IL-24 with or without IL-37.
    [Respiratory Research]

    Full Article

    Sulfur Mustard Analog 2-Chloroethyl Ethyl Sulfide Increases Triglycerides by Activating DGAT1-Dependent Biogenesis and Inhibiting PGC1É‘-Dependent Fat Catabolism in Immortalized Human Bronchial Epithelial Cells

    Using sulfur mustard analog 2-chloroethyl ethyl sulfide, researchers established an in vitro model by poisoning cultured immortalized human bronchial epithelial cells.
    [Toxicology Mechanisms and Methods]

    Abstract

    AIM2 Upregulation Promotes the Metastatic Progression and Pd-L1 Expression in Lung Adenocarcinoma

    Scientists showed that the mRNA levels of absence in melanoma 2 (AIM2), one of the inflammasome members, were extensively upregulated in primary tumors compared to normal tissues derived from the TCGA lung adenocarcinoma database.
    [Cancer Science]

    Full Article

    CircKIF4A Promotes Non-Small Cell Lung Cancer Proliferation and Metastasis through MiR-1238/CLDN14 Axis

    To investigate the functions of circKIF4A, investigators assessed the expression of circKIF4A in NSCLC cells and tissues and performed experiments to determine the detailed functions of circKIF4A in NSCLC, including migration and proliferation.
    [Aging]

    Full Article

    MET Gene Amplification Is a Mechanism of Resistance to Entrectinib in ROS1+ NSCLC

    Utilizing a primary, patient-derived TPM3-ROS1 cell line, the authors derived an entrectinib-resistant line and evaluated proliferation and signaling responses to tyrosine kinase inhibitors.
    [Thoracic Cancer]

    Full Article

    ELANE Promotes M2 Macrophage Polarization by Down-Regulating PTEN and Participates in the Lung Cancer Progression

    The effects of neutrophil elastase (ELANE)-mediated M2 macrophages on lung cancer cell proliferation, migration, and invasion and tumor growth were investigated by in vitro and in vivo experiments after co-culture of macrophage conditioned medium and lung cancer cell lines A549 and H1299.
    [Immunological investigations]

    Abstract

    Explore Antibodies for Epithelial Cell Markers
    REVIEWS

    Accurate Treatment of Small Cell Lung Cancer: Current Progress, New Challenges and Expectations

    To outline the road of SCLC towards precision oncology, scientists summarize the progress and achievements made in precision treatment in SCLC in genomic, transcriptomic, epigenetic, proteomic, and metabolic dimensions.
    [Biochimica et Biophysica Acta-Reviews On Cancer]

    Abstract

    INDUSTRY AND POLICY NEWS

    aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-Ild)

    aTyr Pharma, Inc. announced that the US FDA has granted the company Fast Track designation for its lead therapeutic candidate, efzofitimod, for the treatment of SSc-Ild.
    [aTyr Pharma, Inc.]

    Press Release

    Eloxx Pharmaceuticals Reports Topline Results from Phase II Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

    Eloxx Pharmaceuticals, Inc. announced topline results from the Phase II clinical trial of ELX-02 in combination with ivacaftor in Class 1 CF patients with at least one nonsense mutation.
    [Eloxx Pharmaceuticals, Inc.]

    Press Release

    FEATURED EVENT

    Inborn Errors of Immunity: From Genetics to Basic Immunological Principles to Therapy

    December 5 – 7, 2022
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Research Professional – Pulmonary Vascular Development

    Stanford University – Palo Alto, California, United States

    Postdoctoral Research Scientist – Epithelial Plasticity and Virulence in Lung Adenocarcinoma

    CRUK Beatson Institute for Cancer Research – Glasgow, United Kingdom

    Postdoctoral Research Associate – Lung Cancer Dissemination and Metastasis

    Albert Einstein College of Medicine – Bronx, New York, United States

    Assistant/Associate Professor – Comparative Biomedical Science

    Louisiana State University – Baton Rouge, Louisiana, United States

    Postdoctoral Fellows – Immunology/Bioinformatics

    Boston University – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter